Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Portal Hypertension Clear all
Completed No phase listed Observational

Assessing Outcome After H-graft Shunt Placement

NCT00519610
View directory record Official record
Conditions
Portal Hypertension
Interventions
Chart Review
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 14, 2012 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Not applicable Interventional Results available

Achieving Portal Access With Scorpion Post-Approval Study (APASS)

NCT05765253
View directory record Official record
Conditions
Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions
Scorpion Portal Vein Access Kit, Cook Transjugular Liver Access Set, Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Device · Procedure
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Phase 2 Interventional Results available

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

NCT05027425
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
Interventions
Durvalumab, Tremelimumab, Liver Transplant
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
St Louis, Missouri • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

NCT06082843
View directory record Official record
Conditions
Hypertension, Portal, Liver Cirrhosis
Interventions
Placebo, Avenciguat
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Pasadena, California • Rialto, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting Phase 3 Interventional

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

NCT05470205
View directory record Official record
Conditions
Liver Diseases, Portal Hypertension
Interventions
SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

SHAPE of Portal Hypertension in Children

NCT04720456
View directory record Official record
Conditions
Hypertension, Portal
Interventions
SHAPE measurement using the ultrasound contrast agent Sonazoid (perfluorobutane microbubbles), SHAPE measurement using the ultrasound contrast agent Lumason (sulfur hexafluoride lipid-type A microspheres)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

NCT02053571
View directory record Official record
Conditions
Portal Hypertension
Interventions
TIPS with 3D Overlay
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 11, 2026, 8:20 PM EDT
Completed No phase listed Observational

Achieving Portal Access With Scorpion Post-Approval Study 2

NCT06856655
View directory record Official record
Conditions
Portal Hypertension, Liver Diseases, Ascites Hepatic, Hydrothorax, Vascular Diseases
Interventions
Scorpion Portal Vein Access Kit
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Patient-Portal vs Text-based Hypertension Monitoring Among Black Medicaid/Medicare Patients

NCT05186831
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases
Interventions
Texting, Online patient portal
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Sep 11, 2026, 8:20 PM EDT
Not listed Early Phase 1 Interventional

Body Composition Changes After TIPS and Associated Clinical Outcomes

NCT05420753
View directory record Official record
Conditions
Cirrhosis, Liver, Sarcopenia
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS) creation
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting Phase 2 Interventional

PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

NCT05286814
View directory record Official record
Conditions
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Intrahepatic Bile Duct Cancer, Colorectal Neoplasms, Colorectal Cancer, Cholangiocarcinoma, Bile Duct Neoplasms, Bile Duct Cancer, Adrenocortical Carcinoma (ACC), Adrenal Cortical Carcinoma, Adrenal Gland Cancer, Adrenal Gland Neoplasms, Adrenal Cortex Neoplasms
Interventions
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

NCT05282121
View directory record Official record
Conditions
Liver Diseases, Hypertension, Portal
Interventions
Avenciguat, Empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Pasadena, California • Rialto, California • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Withdrawn Phase 3 Interventional

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

NCT00787436
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Portal Hypertension
Interventions
Thalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 11, 2026, 8:20 PM EDT
Withdrawn Not applicable Interventional

Splenic Embolization for Portal Hypertension

NCT03532750
View directory record Official record
Conditions
Portal Hypertension
Interventions
Particle, Coil
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting Not applicable Interventional

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07046429
View directory record Official record
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting No phase listed Observational

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

NCT06265272
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Cell Carcinoma, Portal Hypertension
Interventions
Injection of a gadolinium contrast agen, Radiotracer Injection, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Recruiting Phase 4 Interventional

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

NCT07058155
View directory record Official record
Conditions
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
Interventions
Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
Procedure · Drug · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Not applicable Interventional Results available

Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness

NCT03352882
View directory record Official record
Conditions
Portal Hypertension, Liver Fibroses
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 79 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Not applicable Interventional

Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure

NCT00670124
View directory record Official record
Conditions
Acute Liver Failure, Intracranial Hypertension
Interventions
Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero
Device
Lead sponsor
Rigshospitalet, Denmark
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Phase 3 Interventional

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

NCT00006398
View directory record Official record
Conditions
Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions
Timolol Maleate, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Not applicable Interventional Results available

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117
View directory record Official record
Conditions
Hypertension
Interventions
Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), Chlorthalidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 11, 2026, 8:20 PM EDT
Terminated Phase 2Phase 3 Interventional

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 11, 2026, 8:20 PM EDT
Completed Phase 2 Interventional Results available

Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension

NCT02960204
View directory record Official record
Conditions
Cirrhosis, Portal Hypertension, Non-alcoholic Steatohepatitis
Interventions
Emricasan, Placebo
Drug
Lead sponsor
Histogen
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
22
States / cities
Pasadena, California • Rialto, California • Palmetto Bay, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 11, 2026, 8:20 PM EDT